#5: WHAT IS YOUR PERSPECTIVE ON THE VALUE OF AUTOMATION IN TODAY’S EVER-CHANGING REGULATORY ENVIRONMENT? | GEORGE SMITH | ARxIUM
#1: WHY DO YOU ADVOCATE AUTOMATING THE STERILE COMPOUNDING PROCESS VS. THE MORE WIDELY USED MANUAL PROCESS? | GEORGE SMITH | ARxIUM
#2: WHAT ARE SOME OF THE BIGGEST MISPERCEPTIONS ABOUT AUTOMATED IV COMPOUNDING SOLUTIONS? | GEORGE SMITH | ARxIUM
#3: IN YOUR EXPERIENCE, WHAT KINDS OF HOSPITALS HAVE BEEN SUCCESSFUL IN AUTOMATING THE STERILE IV COMPOUNDING PROCESS? | GEORGE SMITH | ARxIUM
#4: WHAT STEPS CAN YOU RECOMMEND TO HOSPITALS THAT HAVE DECIDED TO AUTOMATE THAT WILL HELP ENSURE A SMOOTH IMPLEMENTATION? | GEORGE SMITH | ARxIUM
#5: WHAT IS YOUR PERSPECTIVE ON THE VALUE OF AUTOMATION IN TODAY’S EVER-CHANGING REGULATORY ENVIRONMENT? | GEORGE SMITH | ARxIUM
#6: AS A FORMER USER, WHAT IMPACT DID IMPLEMENTING RIVA™ HAVE ON YOUR PHARMACY? | GEORGE SMITH | ARxIUM
#7: AREN’T ALL AVAILABLE AUTOMATED SOLUTIONS “GOOD ENOUGH” WHEN COMPARING THEM TO MANUAL PROCESSES? | GEORGE BOYCE | ARxIUM
#8: WHAT ABOUT THE RIVA™ DESIGN MAKES IT THE INDUSTRY STANDARD FOR SAFETY AND STERILITY? | CRAIG BOYCE | ARxIUM
#9: WHAT MAKES RIVA™ THE RIGHT AUTOMATED SOLUTION FOR 503B OR CENTRAL PROCESSING ENVIRONMENTS? | CRAIG BOYCE | ARxIUM
#10: WHAT IS IT ABOUT RIVA™ THAT HELPS PROMOTE COMPLIANCE WITH EVOLVING REGULATIONS AND GUIDANCE? | CRAIG BOYCE | ARxIUM
#11: WHAT KEY FACTORS HAVE LED TO RIVA™ ACHIEVING MORE THAN 10 MILLION DOSES PREPARED ACCURATELY AND SAFELY? | CRAIG BOYCE | ARxIUM
#12: AS A FORMER USER, WHAT IMPACT DID IMPLEMENTING RIVA™ HAVE ON YOUR PHARMACY? | CRAIG BOYCE | ARxIUM